Slide Deck Summary: Rini et al. 2019 Outcomes

Created using ChatSlide

This presentation will delve into the KEYNOTE-426 clinical trial, exploring the effectiveness of pembrolizumab combined with axitinib compared to sunitinib in treating renal-cell carcinoma. We will review existing VEGF-based treatments and emerging innovations in immunotherapy, while addressing current progression challenges. Detailed methodologies, including patient selection and tumour assessment, will be discussed. Results will highlight notable improvements in survival rates and safety...